Cyclacel Pharmaceuticals, Inc. - Common Stock (CYCC)

Competitors to Cyclacel Pharmaceuticals, Inc. - Common Stock (CYCC)

Acerta Pharma

Acerta Pharma, a wholly-owned subsidiary of AstraZeneca, competes with Cyclacel Pharmaceuticals primarily in the field of innovative cancer therapies, particularly in targeting specific molecular mechanisms. Both companies are focused on developing drugs that aim to improve treatment outcomes for hematologic malignancies. While Cyclacel is working on its own unique approach using cell cycle inhibitors, Acerta has access to AstraZeneca's extensive resources and established pipeline, providing them a competitive advantage in development speed and market reach.

Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics specializes in cell therapy for cancer, particularly with their tumor-infiltrating lymphocyte (TIL) therapy approach. This innovative method may appeal to some of the same patient populations that Cyclacel aims to treat. Iovance's emphasis on advanced cell therapies and its status as a publicly-traded entity with significant capital backing gives it a competitive advantage when it comes to research, development, and healthcare partnerships, therefore, establishing a more prominent presence in the market.

Karyopharm Therapeutics 

Karyopharm Therapeutics is focused on developing drugs targeting nuclear transport, a mechanism that may complement or contrast with the cell cycle inhibition approach of Cyclacel Pharmaceuticals. Both companies are seeking to provide new treatment options for patients with cancer, but Karyopharm's pipeline includes several late-stage candidates that have already progressed further in clinical trials. This timeline advantage positions Karyopharm as a strong competitor, as they may provide first-to-market products in overlapping indications.

Onconova Therapeutics, Inc.

Onconova Therapeutics is another biopharmaceutical company focused on developing novel therapies for cancer. They primarily target the treatment of solid tumors and hematological malignancies, overlapping with Cyclacel's therapeutic interests. Although both companies target similar markets, Onconova's distinct focus on their proprietary drug candidates and partnerships in clinical research gives them an edge in specific clinical trial advancements and possible market launches.